The merger is proceeding as planned with management actively soliciting shareholder support. Monitor for the filing of the definitive proxy statement and the shareholder vote date. The deal is likely to close given AbbVie's resources and the strategic fit, but watch for any regulatory delays or competing bids. APGE stock should trade near the deal price until close.
Price Chart
Executive Summary
Apogee Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) in support of its proposed acquisition by AbbVie, including a principal investigator email urging shareholder approval. The merger, announced on June 22, 2026, is expected to close in Q3 2026, subject to customary conditions including shareholder and regulatory approvals. This filing confirms management's active solicitation and commitment to the deal.
Key Facts
- Merger agreement with AbbVie dated June 18, 2026, via a merger subsidiary structure
- Transaction expected to close in Q3 2026, subject to shareholder approval and regulatory clearances
- Management is actively soliciting proxies in favor of the merger via a principal investigator email
- Apogee's lead asset is zumilokibart (APG777), a potential treatment for inflammatory and immunological conditions
- Deal rationale: AbbVie's global immunology infrastructure to accelerate pipeline development and patient reach
Financial Impact
Acquisition premium not disclosed in this filing; Apogee's market cap is approximately $10.0B
Risk Factors
- Failure to obtain shareholder approval or regulatory clearance could delay or terminate the merger
- Potential competing acquisition proposals or antitrust concerns
- Clinical or regulatory setbacks for zumilokibart could affect deal valuation or closing conditions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-026601 |
| Document: 0001140361-26-026601-index-headers.html | 0001140361-26-026601 |
| Document: 0001140361-26-026601-index.html | 0001140361-26-026601 |
| Document: 0001140361-26-026601.txt | 0001140361-26-026601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access